What did @orianna_williams actually say?
She shared her week 16 update on what she calls "Tresipatad" (tirzepatide), reporting 28 pounds lost. She pays $270 for a three-month supply at 2.5 mg per dose, working out to roughly $22 per injection. She also announced she's self-escalating her dose from 2.5 mg to 3.5 mg after hitting a plateau, and she's linking the compounding pharmacy she uses directly in her bio.
That last part is the one that should make anyone paying attention sit up. She's not describing a supervised titration. She's describing a self-directed dose increase based on her own plateau assessment, purchased from a compounding pharmacy called Paramount Peptides, with a referral link attached.
Does the science back up her weight loss results?
The weight loss itself is plausible. Clinical trial data on tirzepatide is among the strongest we have for any obesity pharmacotherapy right now, so losing weight on it is not in question. What's in question is everything around how she's doing it.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 5, 10, and 15 mg produced average weight reductions of 15%, 19.5%, and 20.9% respectively over 72 weeks. A 28-pound loss at week 16 on a 2.5 mg dose is on the aggressive end of that curve, but not implausible if her starting weight was moderate and she responded well. Individual variation is real. Calling her result fabricated would be unfair.
What the trial data does not support is the idea that self-managed dose escalation from a compounding source is equivalent to the studied protocol. The titration schedule in SURMOUNT-1 was structured and medically supervised. Her escalation from 2.5 mg to 3.5 mg is not a standard studied increment, and 3.5 mg is not a dose that appears in the FDA-approved Mounjaro labeling, which moves from 2.5 mg to 5 mg after four weeks.
What did she get wrong, and what did she get right?
She got the weight loss result right, assuming her reporting is accurate. She got the general cost-effectiveness framing right too. Compounded tirzepatide is substantially cheaper than brand-name Mounjaro, which can run over $1,000 per month without insurance. That price disparity is real and documented.
What she got wrong, or at minimum dangerously incomplete: she's openly describing dose self-escalation with zero mention of a prescriber, and she's directing nearly 100,000 viewers to a compounding pharmacy via a bio link. Paramount Peptides is not an FDA-registered 503B outsourcing facility. Compounded tirzepatide from non-503B sources sits in a regulatory gray zone. The FDA has explicitly warned that compounded versions are not FDA-approved and that quality, potency, and sterility cannot be assumed equivalent to the approved product (FDA Drug Shortages guidance, 2023).
Her "no symptoms on 2.5 mg" reasoning for escalating the dose is also the kind of logic that sounds reasonable on TikTok and is incomplete in a clinical context. Absence of side effects at one dose does not predict tolerability at the next. GI adverse events in SURMOUNT-1 were dose-dependent and most common during escalation phases.
What should you actually know?
Tirzepatide works. The clinical evidence is real. But the version being sold through compounding pharmacies like the one she's linking is not the same product that was studied in those trials, legally or practically. The FDA placed tirzepatide on its drug shortage list, which temporarily allowed compounding, but that designation has been contested and the regulatory status has shifted. As of early 2025, FDA moved to end the shortage designation, which has direct implications for the legality of compounding sources.
Anyone watching this video and thinking about doing the same thing should know a few things. First, you need a legitimate prescription from a licensed provider. Second, the dose increments she describes are not standard. Third, a referral link to a peptide company in a TikTok bio is not medical guidance. If you want tirzepatide, talk to a licensed telehealth provider who can actually review your health history, not someone in a comment section.
- Compounded tirzepatide is not FDA-approved and is not verified as equivalent to Mounjaro or Zepbound.
- Self-escalating doses without provider oversight carries real GI and cardiovascular risk.
- A bio link to a compounding pharmacy is a commercial referral, not a clinical recommendation.